Basilea Pharmaceutica is a Switzerland-based biopharmaceutical company, established in 2000 as a spin-out from Roche with the divestment of its anti-infective portfolio. Basilea was listed on the SIX Swiss Stock Exchange in 2004 and is well funded through its key near-term milestones. Revenue growth will be driven from its two marketed anti-infectives, Cresemba (antifungal – for invasive mould infections) and Zevtera (antibiotic – for hospital infections), which are commercialised globally through partners such as Pfizer and Astellas. It has several oncology assets in clinical development, which represent the next pillar of growth, including derazantinib, a pan-FGFR kinase inhibitor that is in a registrational Phase II study for bile duct cancer and is being tested in urothelial cancer. Lisavanbulin, a potential novel checkpoint inhibitor, is forecast to enter Phase II development by mid-2020.
In this video, CEO David Veitch discusses key revenue drivers and the focus for Basilea’s strategy for 2020.